American Journal of Gastroenterology最新文献_第6页

Response to Borras-Blasco et al. 对Borras-Blasco等人的回应。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-25 DOI: 10.14309/ajg.0000000000003723

María José García, Javier P Gisbert, María Chaparro

引用次数: 0

Mechanisms and Management of Ileus. 肠梗阻的机制和治疗。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-22 DOI: 10.14309/ajg.0000000000003768

Arjun Chatterjee, Renan Prado, Ari Garber, Jean-Paul Achkar

引用次数: 0

Response to Karkra. 对Karkra的回应。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-19 DOI: 10.14309/ajg.0000000000003747

Bharati Kochar, Haley M Zylberberg, Jonas F Ludvigsson

引用次数: 0

Letter to the Editor. 给编辑的信。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-15 DOI: 10.14309/ajg.0000000000003720

Paul J Limburg

引用次数: 0

Letter to the Editor. 给编辑的信。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-08 DOI: 10.14309/ajg.0000000000003620

Shubham Kumar, Rachana Mehta, Ranjana Sah

引用次数: 0

Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. 2型糖尿病患者胰高血糖素样肽-1受体激动剂的胃肠和肝胆安全性

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-03 DOI: 10.14309/ajg.0000000000003760

Chengu Niu, Kefang Sun, Jing Zhang, Ahmed Elkhapery, Kaiwen Zhu, Sheza Malik, Chao Xue, Patrick I Okolo

{"title":"Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.","authors":"Chengu Niu, Kefang Sun, Jing Zhang, Ahmed Elkhapery, Kaiwen Zhu, Sheza Malik, Chao Xue, Patrick I Okolo","doi":"10.14309/ajg.0000000000003760","DOIUrl":"10.14309/ajg.0000000000003760","url":null,"abstract":"Introduction: To evaluate the long-term gastrointestinal (GI) and hepatobiliary safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus, compared with other oral antidiabetic medications.Methods: A retrospective cohort study using the TriNetX network was conducted between 2010 and 2020. After 1:1 propensity score matching, 230,415 patients were included in each group (GLP-1 RAs vs oral antidiabetes mellitus medications). Hazard ratios (HRs) for GI and hepatobiliary outcomes were assessed over 5 years.Results: Among 230,415 matched patients per group, GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy. There were no significant differences in acute pancreatitis, cholecystitis, or cholecystectomy rates between groups. Conversely, GLP-1 RA therapy was not associated with increased incidence of GI cancers. Lower hazard ratios were observed for pancreatic (HR 0.897, P = 0.038), gastric (HR 0.838, P = 0.034), esophageal (HR 0.741, P = 0.001), and colorectal cancer (HR 0.870, P = 0.001), although causality cannot be inferred. No significant differences were observed in biliary cancer or hepatocellular carcinoma.Discussion: In this large real-world cohort study, GLP-1 RA therapy was not associated with increased risk of most serious GI or hepatobiliary outcomes compared with other oral diabetes medications. These findings support the overall GI and hepatobiliary safety of GLP-1 RAs in patients with type 2 diabetes, while underscoring the need for vigilance regarding gastroparesis and intussusception in susceptible individuals. Longer-term studies are warranted to fully evaluate cancer risk.","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protective association of healthy lifestyle behaviours with incident functional constipation: A population-based prospective cohort study. 健康生活方式行为与偶发功能性便秘的保护性关联：一项基于人群的前瞻性队列研究

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-03 DOI: 10.14309/ajg.0000000000003759

Fai Fai Ho, Betty Huan Wang, Yin-Yan Gao, Hong Zheng, Claire Chenwen Zhong, Justin Che Yuen Wu, Yin Ting Cheung, Chun Sing Lam, Maggie Haitian Wang, Irene Xin-Yin Wu, Chen Mao, Zhixiu Lin, Vincent Chi Ho Chung

{"title":"Protective association of healthy lifestyle behaviours with incident functional constipation: A population-based prospective cohort study.","authors":"Fai Fai Ho, Betty Huan Wang, Yin-Yan Gao, Hong Zheng, Claire Chenwen Zhong, Justin Che Yuen Wu, Yin Ting Cheung, Chun Sing Lam, Maggie Haitian Wang, Irene Xin-Yin Wu, Chen Mao, Zhixiu Lin, Vincent Chi Ho Chung","doi":"10.14309/ajg.0000000000003759","DOIUrl":"10.14309/ajg.0000000000003759","url":null,"abstract":"Introduction: The combined effect of some modifiable lifestyle factors on incident functional constipation (FC) is uncertain. This study aimed to evaluate the combined association between healthy lifestyle behaviours and FC incidence.Methods: This population-based prospective cohort study involved 107,457 adults aged 40-70 years who had no FC diagnosis at baseline from the UK Biobank study. The exposure was a sum of five healthy lifestyle behaviours: never smoking, optimal sleep, high level of vigorous physical activity, high dietary quality, and moderate alcohol intake. The outcome was the incidence of FC. The Cox proportional hazards regression model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for their associations.Results: During a median follow-up of 11.7 years, 3591 (3.3%) incident FC cases were recorded. Compared to not exhibiting any of the five healthy lifestyle behaviours, the multivariable adjusted HRs (95% CI) associated with having 1, 2, and 3-5 behaviours for FC incidence were 0.81 (0.74-0.90), 0.72 (0.65-0.80), and 0.60 (0.54-0.67), respectively (P for trend<0.001). Never smoking (HR 0.83, 95% CI 0.77-0.88, P<0.001), high level of vigorous physical activity (HR 0.79, 95% CI 0.74-0.85, P<0.001), and optimal sleep (HR 0.79, 95% CI 0.71-0.87, P<0.001) demonstrated significant independent inverse associations with FC incidence.Discussion: Adopting a higher number of healthy lifestyle behaviours is significantly associated with a reduced incidence of FC in the middle-aged and elderly population, indicating their potential to be a primary prevention strategy. Future research should explore underlying mechanisms and replicate our investigation across diverse populations.","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Wang and Ren. 对王和任的回应。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-03 DOI: 10.14309/ajg.0000000000003696

Fei Han, Jianning Yao

引用次数: 0

Risk of Venous Thromboembolism After Colorectal Cancer Surgery in Patients With and Without Inflammatory Bowel Disease. 伴有和不伴有炎症性肠病的结直肠癌手术后静脉血栓栓塞的风险

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-03 DOI: 10.14309/ajg.0000000000003761

Gencer Kurt, Frederikke Schønfeldt Troelsen, Katalin Veres, Henrik Toft Sørensen, Rune Erichsen

{"title":"Risk of Venous Thromboembolism After Colorectal Cancer Surgery in Patients With and Without Inflammatory Bowel Disease.","authors":"Gencer Kurt, Frederikke Schønfeldt Troelsen, Katalin Veres, Henrik Toft Sørensen, Rune Erichsen","doi":"10.14309/ajg.0000000000003761","DOIUrl":"10.14309/ajg.0000000000003761","url":null,"abstract":"Introduction: Inflammatory bowel disease (IBD) is associated with elevated postoperative mortality in patients undergoing colorectal cancer (CRC) surgery. Venous thromboembolism (VTE) may partially contribute to this elevated mortality. We investigated VTE risk in patients with and without IBD undergoing their first CRC surgery.Methods: We conducted a population-based cohort study using Danish health registries (1996-2021), including all patients undergoing first-time CRC surgery (n = 83,950). Patients with a prior IBD diagnosis were defined as exposed. We calculated the 365-day cumulative risks of VTE and used Cox regression to compute adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs).Results: The 30-day VTE risk was 1.5% in patients with IBD and 0.7% in those without IBD (aHR 1.61; 95% CI 0.86-3.01). During this period, the strongest associations were observed among male patients (aHR 2.26; 95% CI 1.06-4.82), patients aged 60-69 years (aHR 4.63; 95% CI 1.88-11.39), those who had received IBD treatment before surgery (aHR 1.95; 95% CI 0.97-3.95), and patients with active disease (aHR 5.29; 95% CI 1.69-16.56). These associations were primarily driven by patients with ulcerative colitis. HRs remained elevated during 91-365 days.Discussion: Patients with IBD are at elevated risk of VTE after CRC surgery compared with those without IBD. The strongest associations were observed in those who had received IBD treatment before surgery and in those with active disease, particularly patients with ulcerative colitis. These findings emphasize the need for increased VTE awareness and optimizing disease control in patients with high-risk IBD.","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis. ACG临床指南：肝硬化患者围手术期风险评估与管理。

IF 7.6 1区医学

American Journal of Gastroenterology Pub Date : 2025-09-03 DOI: 10.14309/ajg.0000000000003616

Nadim Mahmud, Zachary P Fricker, Lisa M McElroy, Emad Qayed, Robert J Wong, George N Ioannou

{"title":"ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis.","authors":"Nadim Mahmud, Zachary P Fricker, Lisa M McElroy, Emad Qayed, Robert J Wong, George N Ioannou","doi":"10.14309/ajg.0000000000003616","DOIUrl":"10.14309/ajg.0000000000003616","url":null,"abstract":"This guideline presents a comprehensive approach to perioperative risk assessment and management in patients with cirrhosis. Recognizing the unique surgical risks in this population, the guideline emphasizes a multidisciplinary approach to preoperative evaluation, perioperative care, and postoperative follow-up. Key considerations include the severity of liver disease, nonhepatic comorbidities, and surgery-specific factors, with an emphasis on the use of validated cirrhosis-specific risk calculators, such as the VOCAL-Penn Score, for individualized risk stratification. Recommendations highlight preoperative optimization strategies, including nutritional support, management of portal hypertension, correction of hemostatic abnormalities, and addressing frailty and sarcopenia. For patients with decompensated cirrhosis, interventions such as transjugular intrahepatic portosystemic shunt may reduce portal pressure and surgical risks when indicated. Elective surgeries, including cholecystectomy and hernia repair, are advised for select patients with compensated cirrhosis, whereas alternatives to surgery are explored for high-risk patients. The guideline underscores the importance of performing surgeries at high-volume centers with expertise in managing patients with cirrhosis and emphasizes shared decision-making informed by objective risk assessments. Furthermore, it addresses procedure-specific considerations, including the role of bariatric and cardiac surgeries in cirrhotic patients. Through evidence-based recommendations and expert insights, this guideline aims to enhance surgical outcomes and inform clinical decision-making in a growing population of patients with cirrhosis undergoing surgery.","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"120 9","pages":"1968-1984"},"PeriodicalIF":7.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0